



Celgene Corporation
Investor Relations Department
86 Morris Avenue
Summit, NJ 07901
United States

[Visit IR website](#)
[Sign-up for e-mail alerts](#)

NASDAQ: CELG

Last Trade:	88.95
Trade Time:	4:00 PM ET Apr 20, 2018
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	84.25 - 147.17
Volume	N/A

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID[®], VIDAZA[®], THALOMID[®], POMALYST[®]/IMNOVID[®], ABRAXANE[®], OTEZLA[®], ISTODAX[®] and IDHIFA[®]. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Apr 19, 2018

[Celgene Corporation Announces Changes to Its Board of Directors](#)

Apr 17, 2018

[Celgene Corporation to Webcast at Upcoming Investor Conferences](#)

Apr 9, 2018

[Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018](#)

Apr 2, 2018

[Celgene Corporation Announces Departure of President and Chief Operating Officer Scott A. Smith](#)

Mar 28, 2018

[bluebird bio and Celgene Corporation Enter into Agreement to Co-Develop and Co-Promote Anti-BCMA CAR T Cell Therapy bb2121 in the United States](#)

Upcoming Events [\[View all \]](#)

May 4, 2018 9:00 AM ET

[Celgene Corporation Q1 2018 Earnings Conference Call](#)

Events [\[View all \]](#)

Financials [\[View all \]](#)

Feb 7, 2018

[Annual Report \(10-K\)](#)

Apr 27, 2017

[Proxy Statement \(DEF 14A\)](#)

Oct 26, 2017

[Quarterly Report \(10-Q\)](#)

Jul 27, 2017

[Quarterly Report \(10-Q\)](#)

Apr 27, 2017

[Quarterly Report \(10-Q\)](#)